Dimethyl Sulfoxide
Apexbio Technology LLC AM966 1228690-19-4 10mM (in 1mL DMSO)
AM966 (CAS 1228690-19-4) is an orally bioavailable small-molecule antagonist that selectively targets Lysophosphatidic acid type 1 receptor (LPA1) AM966 exhibits potent inhibitory activity against LPA1 receptors from humans and mice with IC50 values of approximately 17 nM and 19 nM respectively demonstrating selectivity over other LPA receptor subtypes (LPA2 5) In vitro AM966 blocks LPA-mediated chemotactic responses in IMR-90 human lung fibroblasts A2058 human melanoma cells and CHO cell lines In vivo AM966 effectively attenuates lung fibrosis inflammation and associated weight loss in bleomycin-induced murine pulmonary fibrosis models highlighting its utility in research on fibrotic diseases
Apexbio Technology LLC BIX 02565 1311367-27-7 10mM (in 1mL DMSO)
BIX 02565 (CAS 1311367-27-7) is a potent inhibitor of ribosomal S6 kinase 2 (RSK2) showing an IC50 of approximately 1 nM RSK activation typically stimulates Na /H exchanger (NHE) crucial for early cellular stress responses involving intracellular pH regulation calcium handling and potential induction of cardiac hypertrophy BIX 02565 also inhibits adrenergic ( 1A 1B 1D 2A 2) imidazoline I2 LRRK2 and PKD1 receptors at varying potencies (IC50 0 052 1 820 M 16 nM and 35 nM respectively) In vivo studies in rats demonstrated dose-dependent decreases in heart rate and mean arterial pressure This compound aids research into signaling pathways relevant to cardiovascular disorders and kinase biology
Sigma Aldrich Fine Chemicals Biosciences Cell freezing Medium-DMSO
Cell freezing medium is a combination of cryoprotectant DMSO with fetal bovine serum. However serum free medium replaces serum with methylcellulose and poloxamer 188 and other additives like ascorbic acid tocopherol and proline.
Medchemexpress LLC Rsl3 10Mm In 1Ml Dmso Reconsti | HY-100218A-10MM-1ML
Rsl3 10Mm In 1Ml Dmso Reconsti
Selleck Chemical LLC JNK-IN-8 - 10mM 1mL in DMSO99.16 purity
JNK-IN-8 - 10mM 1mL in DMSO99.16 purity
Medchemexpress LLC Deg-77 10Mm 1Ml /Dmso Solution | HY-157334-10MM 1ML SOLUTN
Deg-77 10Mm 1Ml /Dmso Solution
Apexbio Technology LLC Ticagrelor 274693-27-5 10mM (in 1mL DMSO)
Ticagrelor (CAS 274693-27-5) is an orally active reversible antagonist targeting the platelet P2Y12 receptor By competitively binding to P2Y12 ticagrelor inhibits ADP-mediated platelet aggregation resulting in dose-dependent suppression of platelet activation and thrombosis in vitro Unlike other P2Y12 inhibitors requiring metabolic activation ticagrelor acts without metabolic transformation though it is primarily metabolized by CYP3A4 and CYP2C19 enzymes This compound is frequently employed in biomedical research exploring platelet function thrombosis mechanisms and drug-drug interactions involving cytochrome P450 enzymes
Apexbio Technology LLC INCB28060 1029712-80-8 10mM (in 1mL DMSO)
INCB28060 (CAS 1029712-80-8) also known as Capmatinib or INC280 is an ATP-competitive inhibitor of the receptor tyrosine kinase c-Met (HGFR) This receptor plays essential roles in cellular processes including embryogenesis healing proliferation invasion and angiogenesis and is frequently overexpressed or mutated in cancers INCB28060 blocks c-Met phosphorylation and downstream signaling exhibiting an IC50 of 0 13 nM In preclinical studies it suppresses proliferation in cancer cell lines (e g SNU-5 S114) and inhibits migration in U-87MG and H441 cells In mouse tumor models oral administration reduces c-Met activation and tumor progression INCB28060 serves as a tool compound for investigating c-Met function in cancer research
Apexbio Technology LLC Avasimibe 166518-60-1 10mM (in 1mL DMSO)
Avasimibe (CAS 166518-60-1) is an orally bioavailable inhibitor of acyl-coenzyme A cholesterol acyltransferase (ACAT) an enzyme involved in cholesterol esterification It exhibits potent inhibition with an IC50 of approximately 60 nM In cell-based studies avasimibe reduces intracellular cholesterol esters in a dose-dependent manner without elevating free cholesterol levels suggesting an advantageous safety profile Additionally avasimibe reduces synthesis and secretion of Apo B 100 a constituent of very low-density lipoprotein (VLDL) in HepG2 cells and increases bile acid synthesis in rat hepatocytes Beyond dyslipidemic modulation and anti-atherogenic activities it influences amyloid precursor protein (APP) trafficking reducing its maturation and subsequent amyloid-beta (A ) peptide generation providing avenues for Alzheimer s disease research
Apexbio Technology LLC Pioglitazone HCl 112529-15-4 10mM (in 1mL DMSO)
Pioglitazone HCl is a potent and highly selective agonist of the peroxisome proliferator-activated receptor gamma (PPAR ) a nuclear receptor involved in glucose and lipid metabolism regulation Acting via PPAR activation pioglitazone increases insulin sensitivity in hepatic adipose and peripheral tissues enhancing insulin-mediated glucose uptake and utilization Pioglitazone requires the presence of insulin to exert its biological activity through receptor activation limiting its application in scenarios characterized by substantial insulin deficiency Clinically pioglitazone HCl has been widely applied in the management and investigation of hyperglycemia associated with type 2 diabetes mellitus (T2DM) Additionally pioglitazone demonstrates effects on lipid regulation notably reducing triglyceride levels and increasing high-density lipoprotein (HDL) cholesterol making it useful in metabolic research
Apexbio Technology LLC BMS-777607 1025720-94-8 10mM (in 1mL DMSO)
BMS-777607 (CAS 1025720-94-8) is an orally bioavailable ATP-competitive inhibitor targeting MET kinase and related receptor tyrosine kinases It selectively inhibits members of the MET family including RON MET Tyro-3 and Axl with IC50 values of 1 8 nmol/L 3 9 nmol/L 4 3 nmol/L and 1 1 nmol/L respectively At higher doses it also inhibits additional tyrosine kinases such as Mer Flt-3 Aurora B Lck and VEGFR2 BMS-777607 has been shown to suppress c-Met autophosphorylation (IC50 20 nmol/L) thereby impairing tumor xenograft growth and metastatic phenotypes supporting its utility in oncological research models exploring MET-driven tumorigenesis and cancer progression
Apexbio Technology LLC Tiplaxtinin(PAI-039)(Synonyms: Tiplaxtinin, PAI-039, Tiplaxtinin (PAI-039), Tiplaxitin, PAI1 inhibitor, PAI-1 antagonist, RWJ-676070), 10mM (in 1mL DMSO), CAS: 393105-53-8.
Tiplaxtinin (PAI-039 CAS 393105-53-8) is an orally bioavailable small molecule inhibitor targeting plasminogen activator inhibitor-1 (PAI-1) a physiological regulator of the plasminogen activation system Elevated PAI-1 levels stabilize thrombi by inhibiting tissue- and urokinase-type plasminogen activators Tiplaxtinin binds selectively to PAI-1 with a Kd of approximately 480 nM and inhibits its activity with an IC50 value around 2 7 M In animal models oral administration of Tiplaxtinin significantly delayed arterial thrombus-induced occlusion supporting its utility as a research tool for studying fibrinolytic pathways and thrombotic disorders
Apexbio Technology LLC vinblastine 865-21-4 10mM (in 1mL DMSO)
Vinblastine is a naturally-derived alkaloid isolated from Catharanthus roseus It functions as a microtubule inhibitor by binding specifically to tubulin disrupting microtubule polymerization and thereby arresting mitosis at metaphase Due to this mechanism vinblastine is widely investigated for antitumor activities and is commonly employed in biomedical research to study cell division cytoskeletal dynamics and therapeutic interventions in oncology Vinblastine should be stored under sealed dry and cool conditions to maintain molecular integrity and biological activity